Yes, I have growth forecasted for long term. But the problem for IG CIDP products is going to be VYVGART. At the moment efficacy rates are similar, but much easier to take the medicine. If this case CSL could loose many new patients over next decade. Current patients may not move over, but if it takes only 1 hour take against 8 hours, the new patients will not hesitate. Once you start to factor this possible development, the gains in efficiency may be loss product volume itself. I have forecasted continuous growth for vaccine segment and Vifor. But that may not be enough to push price towards $300 in the near future, specially considering the current interest rates. You are talking about close to 30 pe to get there. I have reservations.
Yes, I have growth forecasted for long term. But the problem for...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.99 |
Change
-2.010(0.68%) |
Mkt cap ! $142.3B | |||
| Open | High | Low | Value | Volume |
| $294.28 | $295.68 | $293.59 | $36.32M | 123.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 29 | $293.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $294.01 | 14 | 3 |
View Market Depth
| Last trade - 11.38am 18/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |